5.4% after 12 hr, n=205
When speaking with your GP, it may be helpful to discuss: Your current BMI and any weight-related health conditions Whether you meet the criteria for existing licensed weight management medications Your reproductive health status, contraception, and any plans for pregnancy Any personal or family history of thyroid disease, pancreatitis, or gallbladder problems Your interest in clinical trials, should you wish to explore participation in retatrutide research Staying informed about emerging treatments is entirely reasonable, but it is important to do so through reliable sources such as the NHS website (nhs.uk), NICE (nice.org.uk), and the MHRA (gov.uk/mhra)
It is mainly produced by the liver (accounting for 75 % of circulating IGF-1) secondary to growth hormone (GH) and insulin endocrine stimulation in the liver
PAS is supporting research to explore more flexible and less resource-intensive methods, including: Self-Administration : Advocating for more patients (if they are willing) to be taught how to administer their own injections safely at home, reducing reliance on GP appointments
These findings are consistent with data accessed on February 9, 2026
In some cases, it may be best to wait until your symptoms resolve before starting the new GLP-1